Latest Period
Q2 2026
Security Snapshot
AbCellera Biologics Inc. - Common Shares, no par value per share (ABCL) Institutional Ownership
CUSIP: 00288U106
13F Institutional Holders and Ownership History from Q4 2020 to Q2 2026
Institutions Reporting
151
Shares (Excl. Options)
116,098,269
Price
$7.85
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Shares, no par value per share
- Symbol
- ABCL on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 116,098,269
- Total 13F value
- $908,853,431
- Portfolio coverage rank
- 0%
- Share change
- -8,064,396
- Value change
- -$39,181,194
- Number of holders
- 151
- Shares outstanding
- 305,667,944
- SEC-reported price per share
- $10.97
- Insider filing price
- $10.97
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- ABCL - AbCellera Biologics Inc. - Common Shares, no par value per share is tracked under CUSIP 00288U106.
- 151 institutions reported positions in Q2 2026.
- 2 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 137 to 151 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $433,839,784 to $908,853,431.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 151 institutions filings for Q2 2026.
Security key
00288U106
Latest holder period
Q2 2026
13F holders
151
13D/G owners
2
CIK / CUSIP context first
Open Q2 2026 holders
ABCL full holder history
AbCellera Biologics Inc. SEC filings
AbCellera Biologics Inc. company facts
AbCellera Biologics Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 00288U106:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
2
Security
ABCL
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | 11% | $120,824,425 | 33,012,138 | Baker Bros. Advisors LP | 30 Apr 2026 | |||
| BAILLIE GIFFORD & CO | 4.4% | $32,881,493 | 12,894,703 | BAILLIE GIFFORD & CO | 30 Sep 2024 |
As of 30 Jun 2026, 151 institutional investors reported holding 116,098,269 shares of AbCellera Biologics Inc. - Common Shares, no par value per share (ABCL). This represents 38% of the company’s total 305,667,944 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
35%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | 11% | 33,012,138 | +9% | 1.3% | $259,145,283 |
| Capital World Investors | 4.4% | 13,588,349 | +1.7% | 0.01% | $106,668,540 |
| TWO SIGMA INVESTMENTS, LP | 3.4% | 10,437,431 | -1.2% | 0.06% | $81,933,833 |
| TD Waterhouse Canada Inc. | 3.1% | 9,568,149 | +0.04% | 0.19% | $72,623,873 |
| BANK OF AMERICA CORP /DE/ | 2% | 6,141,539 | +105% | 0% | $48,211,081 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1.4% | 4,317,206 | -43% | 0.01% | $33,890,067 |
| ArrowMark Colorado Holdings LLC | 1.3% | 4,105,095 | 0% | 1.3% | $32,224,996 |
| BlackRock, Inc. | 1.2% | 3,805,309 | -5.8% | 0% | $29,871,676 |
| Driehaus Capital Management LLC | 0.94% | 2,864,729 | -29% | 0.13% | $22,488,123 |
| TUDOR INVESTMENT CORP ET AL | 0.67% | 2,063,191 | -9.3% | 0.07% | $16,196,049 |
| MARSHALL WACE, LLP | 0.62% | 1,902,191 | +429% | 0.01% | $14,932,200 |
| UBS Group AG | 0.61% | 1,870,633 | -56% | 0% | $14,684,469 |
| MORGAN STANLEY | 0.55% | 1,669,014 | -25% | 0% | $13,101,760 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 0.52% | 1,587,870 | 0% | $12,465,000 | |
| CITADEL ADVISORS LLC | 0.52% | 1,586,512 | +17% | 0.01% | $12,454,119 |
| NATIONAL BANK OF CANADA /FI/ | 0.4% | 1,233,014 | +88415% | 0.01% | $9,679,124 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 0.34% | 1,039,927 | 0% | $8,163,427 | |
| RENAISSANCE TECHNOLOGIES LLC | 0.32% | 990,929 | -34% | 0.01% | $7,778,793 |
| Counterpoint Mutual Funds LLC | 0.32% | 971,643 | 0.75% | $7,627,398 | |
| STATE STREET CORP | 0.24% | 731,362 | +0.16% | 0% | $5,741,192 |
| HRT FINANCIAL LP | 0.23% | 705,506 | -43% | 0.01% | $5,538,000 |
| DNB Asset Management AS | 0.22% | 677,479 | 0.01% | $5,318,210 | |
| Guardian Partners Inc. | 0.19% | 595,998 | -67% | 0.42% | $4,678,584 |
| Intellectus Partners, LLC | 0.18% | 551,583 | +1% | 0.75% | $4,329,925 |
| Alyeska Investment Group, L.P. | 0.17% | 526,577 | -80% | 0.01% | $4,133,629 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
23
Latest
Q2 2026
Rows shown
1-23 of 23
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 116,098,269 | $908,853,431 | -$39,181,194 | $7.85 | 151 |
| 2026 Q1 | 124,252,829 | $433,839,784 | +$55,053,547 | $3.49 | 137 |
| 2025 Q4 | 108,415,371 | $370,606,742 | -$10,167,392 | $3.42 | 145 |
| 2025 Q3 | 104,032,627 | $524,646,193 | +$3,617,959 | $5.03 | 140 |
| 2025 Q2 | 107,623,463 | $370,594,083 | -$42,109,114 | $3.43 | 127 |
| 2025 Q1 | 124,693,841 | $278,605,461 | +$21,793,003 | $2.23 | 127 |
| 2024 Q4 | 113,909,183 | $333,909,974 | +$23,930,958 | $2.93 | 145 |
| 2024 Q3 | 105,626,999 | $274,569,746 | -$27,524,912 | $2.60 | 139 |
| 2024 Q2 | 114,251,365 | $337,827,363 | -$12,985,717 | $2.96 | 146 |
| 2024 Q1 | 120,885,782 | $546,343,961 | +$6,435,245 | $4.53 | 153 |
| 2023 Q4 | 119,177,804 | $681,087,686 | -$3,743,767 | $5.71 | 141 |
| 2023 Q3 | 120,025,395 | $551,791,208 | -$29,473,838 | $4.60 | 137 |
| 2023 Q2 | 124,831,655 | $809,068,808 | -$42,715,484 | $6.46 | 167 |
| 2023 Q1 | 130,072,488 | $980,706,858 | +$9,956,814 | $7.54 | 181 |
| 2022 Q4 | 138,959,875 | $1,408,301,843 | +$64,970,441 | $10.13 | 198 |
| 2022 Q3 | 132,080,272 | $1,309,587,378 | +$125,586,082 | $9.89 | 185 |
| 2022 Q2 | 117,984,795 | $1,259,732,308 | +$77,596,210 | $10.65 | 160 |
| 2022 Q1 | 113,127,329 | $1,100,172,856 | -$30,931,776 | $9.75 | 126 |
| 2021 Q4 | 114,533,051 | $1,628,519,417 | +$98,165,187 | $14.30 | 120 |
| 2021 Q3 | 98,697,276 | $1,977,505,786 | +$155,909,310 | $20.04 | 115 |
| 2021 Q2 | 90,556,840 | $1,986,081,198 | +$169,321,459 | $22.00 | 111 |
| 2021 Q1 | 71,121,706 | $2,415,006,720 | +$64,105,935 | $33.96 | 82 |
| 2020 Q4 | 68,103,635 | $2,740,470,000 | +$2,587,818,000 | $40.24 | 58 |